Director Regulatory Affairs
Alnylam Pharmaceuticals
Director Regulatory Affairs
Alnylam Pharmaceuticals
Develops RNAi-based therapies for genetic diseases
Director, Regulatory Affairs, Global Labeling Strategy (US)
Overview
The Director of Global Labeling (GL) US will play a lead role in building and refining Alnylam’s global labeling strategy processes and capabilities; supervise junior labeling strategists and provide strategic guidance in the development and maintenance of Company Core Data Sheets (CCDS), country product information (CPI) for Alnylam’s products, and development of Target Label Profiles (TLP) for investigational therapies or uses.
Summary of Key Responsibilities
Qualifications
#LI-AB1 #LI-Virtual
About Alnylam
We are the leader in RNAi therapeutics – a revolutionary approach with the potential to transform the lives of people with rare and common diseases. Built on Nobel Prize-winning science, Alnylam has delivered the breakthroughs that made RNAi therapeutics possible and are just at the beginning of what’s possible. Our deep pipeline, late-stage programs, and bold vision reflect our core values: fierce innovation, passion for excellence, purposeful urgency, open culture and commitment to people. We're proud to be a globally recognized top employer, where an authentic, inclusive culture and breakthrough thinking fuel one another.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. Qualified applicants will receive consideration for employment without regard to their sex, gender or gender identity, sexual orientation, race, color, ethnicity, national origin, ancestry, citizenship, religion, creed, physical or mental disability, pregnancy status or related conditions, genetic information, veteran or military status, marital or familial status, political affiliation, age, or any other factor protected by federal, state, or local law. Alnylam is an E-Verify Employer.
Before applying, please review Alnylam's Candidate Privacy Notice regarding how Alnylam handles Personal Data you provide with your application for employment.
The pay range below reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on a number of factors including, but not limited to, relevant experience, skills, and education. This role is eligible for an annual short-term incentive award (e.g., bonus or sales incentive) and an annual long-term incentive award (e.g., equity).
Alnylam’s robust Total Rewards package is designed to support your overall health and well-being. We offer comprehensive benefits including medical, dental, and vision coverage, life and disability insurance, a lifestyle reimbursement program, flexible spending and health savings accounts and a 401(k)with a generous company match. Eligible employees enjoy paid time off, wellness days, holidays, and two company-wide recharge breaks. We also offer generous family resources and leave. Our commitment to your well-being reflects our belief that caring for our people fuels the impact we create together.
Learn more about these and additional benefits offered by Alnylam by visiting the Benefits section of the Careers website: https://www.alnylam.com/careers
U.S. Pay Range 201700 - 272900 USD
Develops RNAi-based therapies for genetic diseases
Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.
Explore more opportunities at Alnylam Pharmaceuticals